AUGUST 2022LIFE SCIENCES REVIEW9and cryogenic (­196 °C) for advanced therapy medicinal products (ATMPs). All cold chain storage solutions have full operational redundancy and incorporate real-time monitoring, ensuring the products do not experience any temperature excursion or exposure to conditions that may compromise quality or integrity. As part of our "build today for future demand" ethos, PCI plans to double the capacity of refrigerated (2­8 °C) storage across our UK sites, which in absolute terms means in excess of 3000 pallet locations.In line with our approach to always deliver best-in-class technologically advanced solutions, PCI has collaborated with Marchesini on this latest investment, further building on a successful and longstanding relationship. (Marchesini is a leading global provider of automated pharmaceutical packaging machines, based in Italy's "Packaging Valley" in Emilia Romagna.)Across PCI's European sites, the automated parenteral packaging lines will deliver a combined initial capacity of over 50 million PFS units and 70 million vials per year, including fully integrated inspection for the critical to quality attributes (CQAs). Serialization and aggregation capabilities are also inbuilt as standard. The use of integrated and multi-layered Serialization technology ensures the highest standards of regulatory compliance, ultimately providing patients with safe and effective medicines. The new Biotech packaging lines across our European facilities will commence operations in 2022. Furthermore, to support global commercial product launches, PCI provides customers with a dedicated New Product Introduction (NPI) team to ensure a seamless technical transfer into our facilities, aiding speed to market. Globally, we support in excess of 50 product launches each year, 15 of which are from the European facilities. Our committed team of experienced professionals ensure excellence in customer service for the duration of the project, whilst providing the flexibility required to meet the ever-changing demands of the product lifecycle.In addition to our Biotech packaging capabilities, PCI is able to provide a range of services for more traditional oral solid dose formulations, including blistering and bottling. PCI also supports the packaging of controlled drug substances, hormones and drug products containing highly potent APIs, along with medical device packaging services. In addition, we are able to offer in-house packaging development services from design to commercialization, including the ability to develop prototypes using photorealistic rendering, rapid prototyping technologies and lab scale equipment.Importantly, all services are supported by our in-house analytical laboratories providing full global release testing including release into the EU. Leading global CDMO, PCI has further expanded its biotech packaging capabilities with investment across Europe in both the UK and Ireland facilitiesPCI ­ EXPANDING ITS BIOTECH FOOTPRINT
< Page 8 | Page 10 >